Freeline Therapeutics Holdings plc (FRLN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Freeline Therapeutics Holdings plc (FRLN) trades at $6.49 with AI Score 44/100 (Weak). Freeline Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies for inherited systemic diseases. Market cap: 29M, Sector: Healthcare.
Last analyzed: Mar 3, 2026Freeline Therapeutics Holdings plc (FRLN) Healthcare & Pipeline Overview
Freeline Therapeutics pioneers transformative AAV gene therapies for inherited diseases, offering potential cures for hemophilia B, Fabry disease, and Gaucher disease, with ongoing Phase 1/2 clinical trials demonstrating promising early results and a strong pipeline for future growth.
Investment Thesis
Freeline Therapeutics presents a notable research candidate due to its innovative AAV gene therapy platform and promising clinical pipeline. The company's lead candidate, FLT180a, has shown encouraging early results in Phase 1/2 trials for hemophilia B, with the potential to significantly reduce or eliminate the need for factor IX infusions. With a market cap of approximately $0.03 billion, Freeline offers significant upside potential if its clinical programs are successful. Key value drivers include positive clinical trial data readouts for FLT180a, FLT190, and FLT201, as well as potential partnerships or collaborations to advance its pipeline. The company's focus on inherited systemic diseases with high unmet needs positions it well for future growth. The company's low Beta of 0.66 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- FLT180a, the lead product candidate, is in Phase 1/2 clinical trials for hemophilia B, targeting a significant unmet need.
- FLT190 is in Phase 1/2 clinical trial for Fabry disease, expanding the pipeline into another inherited metabolic disorder.
- FLT201 is a liver-directed gene therapy candidate in Phase 1/2 clinical trial for type 1 Gaucher disease, further diversifying the pipeline.
- The company was founded in 2015, indicating a relatively young but focused approach to gene therapy development.
- The company has 152 employees, suggesting a lean and efficient operational structure.
Competitors & Peers
Strengths
- Proprietary AAV gene therapy platform.
- Clinical-stage pipeline with multiple product candidates.
- Experienced management team with expertise in gene therapy development.
- Focus on inherited systemic diseases with high unmet needs.
Weaknesses
- Clinical-stage company with no currently approved products.
- High cash burn rate associated with clinical development.
- Reliance on successful clinical trial outcomes.
- Small market capitalization.
Catalysts
- Upcoming: Data readouts from Phase 1/2 clinical trials of FLT180a for hemophilia B.
- Upcoming: Data readouts from Phase 1/2 clinical trials of FLT190 for Fabry disease.
- Upcoming: Data readouts from Phase 1/2 clinical trials of FLT201 for Gaucher disease.
- Ongoing: Enrollment and progress in ongoing clinical trials.
- Ongoing: Potential for partnerships or collaborations to advance pipeline.
Risks
- Potential: Clinical trial failures or delays could negatively impact the company's valuation.
- Potential: Regulatory hurdles and approval timelines could delay or prevent the commercialization of its products.
- Potential: Competition from other gene therapy companies could limit market share.
- Ongoing: High cash burn rate requires ongoing financing, potentially leading to dilution.
- Ongoing: The company's small market capitalization makes it vulnerable to volatility.
Growth Opportunities
- Expansion of FLT180a into broader hemophilia B patient populations: The current Phase 1/2 trial focuses on adult males. Expanding the trial to include female patients and younger age groups could significantly increase the addressable market. The global hemophilia B market is projected to reach billions of dollars, offering substantial revenue potential for a successful gene therapy.
- Advancement of FLT190 for Fabry disease: Fabry disease represents another significant market opportunity for Freeline. Positive data from the Phase 1/2 trial could lead to accelerated development and potential regulatory approval. The Fabry disease market is estimated to be worth hundreds of millions of dollars, providing a valuable revenue stream.
- Development of FLT201 for Gaucher disease: Gaucher disease is a rare genetic disorder with limited treatment options. FLT201 has the potential to address this unmet need and capture a portion of the Gaucher disease market. The global Gaucher disease market is expected to grow, driven by increasing awareness and diagnosis.
- Strategic partnerships and collaborations: Freeline could pursue partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its gene therapy programs. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's growth prospects.
- Expansion into new therapeutic areas: Freeline's AAV gene therapy platform could be applied to other inherited systemic diseases beyond hemophilia B, Fabry disease, and Gaucher disease. Exploring new therapeutic areas could significantly expand the company's pipeline and market potential. This would require further investment in research and development.
Opportunities
- Positive clinical trial data readouts for FLT180a, FLT190, and FLT201.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Potential for accelerated regulatory pathways for gene therapies.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and approval timelines.
- Competition from other gene therapy companies.
- Potential for dilution through future financing activities.
Competitive Advantages
- Proprietary AAV vector technology platform.
- Expertise in liver-directed gene therapy.
- Clinical-stage pipeline with promising early results.
- Intellectual property protection for its product candidates.
About FRLN
Freeline Therapeutics Holdings plc, founded in 2015 and headquartered in Stevenage, UK, is a clinical-stage biotechnology company dedicated to developing potentially curative gene therapies for individuals suffering from inherited systemic diseases. The company leverages its expertise in adeno-associated virus (AAV) vector technology to design and develop gene therapies that address the underlying genetic causes of these diseases. Freeline's lead product candidate, verbrinacogene setparvovec (FLT180a), is a gene therapy in Phase 1/2 clinical trials for the treatment of hemophilia B, a genetic bleeding disorder caused by a deficiency in clotting factor IX. FLT180a aims to provide long-term factor IX expression, reducing or eliminating the need for regular infusions of clotting factor. The company's pipeline also includes FLT190, a gene therapy in Phase 1/2 clinical trial for Fabry disease, and FLT201, a liver-directed gene therapy candidate in Phase 1/2 clinical trial for type 1 Gaucher disease. These programs reflect Freeline's commitment to addressing significant unmet needs in inherited metabolic disorders. Freeline continues to advance its research programs in various indications for systemic gene therapy, aiming to expand its portfolio of innovative treatments for patients with limited therapeutic options.
What They Do
- Develops adeno-associated virus (AAV) vector-mediated gene therapies.
- Focuses on inherited systemic debilitating diseases.
- Conducts Phase 1/2 clinical trials for its product candidates.
- Targets diseases like hemophilia B, Fabry disease, and Gaucher disease.
- Aims to provide long-term therapeutic benefits through gene therapy.
- Utilizes liver-directed gene therapy approaches.
Business Model
- Develops proprietary gene therapy product candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered programs.
- Funds research and development through venture capital and public offerings.
Industry Context
Freeline Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the gene therapy sector. The market for gene therapies is experiencing significant growth, driven by advances in vector technology and increasing regulatory approvals. The competitive landscape includes companies such as ALLK (Allakos Inc), ANGN (Angion Biomedica Corp), ANPC (AnPac Bio-Medical Science Co Ltd), ELEV (Elevation Oncology Inc), and LMNL (Liminal BioSciences Inc), all of whom are pursuing innovative approaches to treating various diseases. Freeline's focus on AAV-mediated gene therapies for inherited systemic diseases positions it within a niche market with substantial growth potential.
Key Customers
- Patients suffering from inherited systemic diseases (hemophilia B, Fabry disease, Gaucher disease).
- Healthcare providers who treat these patients.
- Pharmaceutical companies seeking to in-license or acquire gene therapy assets.
Financials
Chart & Info
Freeline Therapeutics Holdings plc (FRLN) stock price: $6.49 (+0.01, +0.15%)
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 11, 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Apr 28, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Apr 26, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Oct 10, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FRLN.
Price Targets
Wall Street price target analysis for FRLN.
MoonshotScore
What does this score mean?
The MoonshotScore rates FRLN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
FRLN Healthcare Stock FAQ
What does Freeline Therapeutics Holdings plc (FRLN) do?
Freeline Therapeutics is a clinical-stage biotechnology company specializing in the development of adeno-associated virus (AAV) vector-mediated gene therapies for inherited systemic diseases. Their primary focus is on creating potentially curative treatments for conditions like hemophilia B, Fabry disease, and Gaucher disease. The company's business model revolves around advancing its pipeline of gene therapy candidates through clinical trials, with the ultimate goal of partnering with or being acquired by larger pharmaceutical companies for commercialization. This involves significant research and development efforts, as well as strategic collaborations to accelerate the development and delivery of these innovative therapies to patients in need.
Is FRLN stock worth researching?
Evaluating whether FRLN stock is worth researching requires careful consideration of its potential and risks. The company's innovative AAV gene therapy platform and promising clinical pipeline, particularly FLT180a for hemophilia B, present significant upside potential. However, as a clinical-stage company with a small market cap of $0.03 billion and negative P/E ratio of -0.29, Freeline faces substantial risks, including clinical trial failures and the need for ongoing financing. Investors should weigh the potential for significant returns against the inherent uncertainties of biotechnology investing before making a decision. The low Beta of 0.66 suggests lower volatility than the overall market, but this does not eliminate the significant risks associated with investing in a clinical-stage biotech company.
What are the risks of investing in FRLN?
Investing in Freeline Therapeutics (FRLN) carries several significant risks inherent to clinical-stage biotechnology companies. One major risk is the potential for clinical trial failures or delays, which could severely impact the company's valuation and future prospects. Regulatory hurdles and approval timelines also pose a risk, as the path to market for gene therapies can be lengthy and uncertain. Furthermore, Freeline faces competition from other companies developing gene therapies for similar indications. The company's high cash burn rate necessitates ongoing financing, potentially leading to dilution of existing shareholders. These factors, combined with the company's small market capitalization, contribute to a higher risk profile for FRLN stock.
What catalysts could move FRLN stock?
Several catalysts could potentially drive movement in FRLN stock. Upcoming data readouts from the Phase 1/2 clinical trials of FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease are key events to watch. Positive clinical trial results could generate significant investor enthusiasm and drive the stock price higher. Additionally, any strategic partnerships or collaborations with larger pharmaceutical companies could provide a boost to the company's credibility and financial resources, leading to positive market sentiment. Progress in enrolling patients and advancing the ongoing clinical trials will also be closely monitored by investors. Successful execution of these milestones could serve as positive catalysts for FRLN stock.
What is FRLN stock price target?
As of March 3, 2026, there is no readily available analyst consensus price target for FRLN stock due to its small market capitalization and limited analyst coverage. Determining a fair value estimate would require a detailed analysis of the company's clinical pipeline, probability of success for its product candidates, and potential future revenue streams. Investors should conduct their own due diligence and consider factors such as the company's cash position, burn rate, and potential for future dilution when assessing the intrinsic value of FRLN stock. Given the uncertainties inherent in clinical-stage biotechnology companies, any price target should be viewed with caution.
What are the key factors to evaluate for FRLN?
Freeline Therapeutics Holdings plc (FRLN) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary AAV gene therapy platform.. Primary risk to monitor: Potential: Clinical trial failures or delays could negatively impact the company's valuation.. This is not financial advice.
How frequently does FRLN data refresh on this page?
FRLN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FRLN's recent stock price performance?
Recent price movement in Freeline Therapeutics Holdings plc (FRLN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary AAV gene therapy platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and thorough due diligence.